Drugs / Iscador Qu
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02948309 | Jun 2016 → Sep 2022 | malignant exocrine pancreas neoplasm | Karolinska University Hospital | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06408688 Comparator | Jun 2024 → Nov 2026 expected | neoplasm | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iscador Qu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06408688 ↗ |
| Known as | Mistletoe extract | “Mistletoe extract (Iscador Qu)” NCT02948309 ↗ |
| Route | Subcutaneous | “Mistletoe extracts are usually administered subcutaneously.” NCT02948309 ↗ |